Skip to main content
logo
NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
35.44
-0.30 (-0.84%)
At close: May 22, 2026, 4:00 PM EDT
36.60
+1.16 (3.27%)
After-hours: May 22, 2026, 4:58 PM EDT

NAMS Revenue

NewAmsterdam Pharma Company had revenue of $3.04M in the quarter ending March 31, 2026, with 2.08% growth. This brings the company's revenue in the last twelve months to $22.57M, down -52.13% year-over-year. In the year 2025, NewAmsterdam Pharma Company had annual revenue of $22.50M, down -50.61%.

Revenue (ttm)
$22.57M
Revenue Growth
-52.13%
P/S Ratio
183.61
Revenue / Employee
$225,650
Employees
100
Market Cap
4.14B

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 202522.50M-23.06M-50.61%
Dec 31, 202445.56M31.47M223.37%
Dec 31, 202314.09M-88.60M-86.28%
Dec 31, 2022102.69M--
Dec 31, 2021---
Dec 31, 2020 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
ACADIA Pharmaceuticals1.10B
Caris Life Sciences907.29M
Catalyst Pharmaceuticals596.96M
Travere Therapeutics536.20M
Ligand Pharmaceuticals274.48M
Crinetics Pharmaceuticals18.07M
CRISPR Therapeutics AG4.10M
Dianthus Therapeutics1.34M
Revenue Rankings

NAMS News

More News